ACTIVE

UCB BIOPHARMA

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

113,8 M €

+1244.9% YoY

Revenue

3,6 Md €

+2.3% YoY

Equity

1,2 Md €

+6.6% YoY

Workforce

1 395,2 ETP

+5.9% YoY

What does UCB BIOPHARMA do?

UCB BIOPHARMA is a Private limited company incorporated in 2013. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Anderlecht. It employs on average 1 395,2 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0543.573.053

Incorporation

24/12/2013

Legal form

Private limited company

Registered office

Allée de la Recherche 60
1070 Anderlecht · BruxellesSee on map

Contributed capital

1 017 715 816,00 €

Latest accounts

31/12/2025

Average workforce

1 395,2 ETP

Activities (NACE)

21201Manufacture of pharmaceutical preparations· main 72101Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology

Joint committees (1)

Signals

ProfitablePositive cashflowPositive EBITDAHealthy social debtsHigh revenue

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 10 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2015		2014
Income statement
Revenue	3,6 Md €	+2.3%	3,6 Md €	+36.0%	2,6 Md €	-8.2%	2,9 Md €	-13.4%	3,3 Md €	-8.5%	3,6 Md €	+23.6%	2,9 Md €	+21.6%	2,4 Md €	+28.8%	1,9 Md €	+47.5%	1,3 Md €
EBITDA	1,8 Md €	+2.6%	1,8 Md €	+81.2%	975,8 M €	-18.6%	1,2 Md €	-25.8%	1,6 Md €	-14.3%	1,9 Md €	+39.8%	1,3 Md €	+27.2%	1,1 Md €	+52.6%	695,1 M €	+24.5%	558,4 M €
Operating result	135,6 M €	+1579%	-9,2 M €	+98.8%	-751,6 M €	-5.5%	-712,3 M €	-20.6%	-590,6 M €	-186%	-206,5 M €	+62.4%	-548,8 M €	+33.5%	-824,9 M €	-32.7%	-621,5 M €	-149%	-249,1 M €
Net result	113,8 M €	+1245%	8,5 M €	+101%	-676,9 M €	-30.3%	-519,5 M €	-1.8%	-510,4 M €	-126%	-225,3 M €	+60.4%	-569,4 M €	+31.2%	-827,9 M €	-185%	-290,8 M €	-3117%	9,6 M €
Balance sheet
Equity	1,2 Md €	+6.6%	1,1 Md €	+276%	293,4 M €	-69.8%	970,3 M €	+98.1%	489,8 M €	-51.0%	1,0 Md €	-18.4%	1,2 Md €	-13.8%	1,4 Md €	-48.8%	2,8 Md €	-9.5%	3,1 Md €
Total assets	7,2 Md €	+14.5%	6,2 Md €	+21.6%	5,1 Md €	-3.2%	5,3 Md €	-17.3%	6,4 Md €	-9.0%	7,0 Md €	+5.9%	6,7 Md €	-9.4%	7,3 Md €	+39.8%	5,3 Md €	-2.0%	5,4 Md €
Cash	153,8 M €	+494%	25,9 M €	-70.3%	87,1 M €	-0.3%	87,4 M €	-64.3%	244,9 M €	-61.4%	634,5 M €	-2.6%	651,1 M €	+158%	252,7 M €	+432%	47,5 M €	-93.0%	673,7 M €
Debts	5,6 Md €	+18.9%	4,7 Md €	+7.7%	4,3 Md €	+15.0%	3,8 Md €	-28.5%	5,3 Md €	-4.4%	5,5 Md €	+7.6%	5,1 Md €	-7.9%	5,6 Md €	+143%	2,3 Md €	+5.2%	2,2 Md €
Other
Workforce	1 395,2 ETP	+5.9%	1 317,9 ETP	+3.8%	1 269,4 ETP	+0.1%	1 267,9 ETP	+2.7%	1 235,1 ETP	+12.5%	1 097,9 ETP	+8.4%	1 012,9 ETP	+5.5%	960,0 ETP	+10.7%	867,0 ETP	-3.2%	895,4 ETP

Estimate

Indicative valuation

As an indication, this company is worth

more than 1.000 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 4 active · 15 ended

Active mandates

Alistair HENRY

Director · since 01 juillet 2024

Active

Denelle J. WAYNICK JOHNSON

Director · since 01 avril 2023

Active

Sandrine DUFOUR

Director · since 28 septembre 2020

Active

Jean-Luc FLEURIAL

Director · since 12 décembre 2017

Active

Ended mandates

William SILBEY

Director · since 22 mars 2019 · until 31 mars 2023

Ended

William SILBEY

Director · since 22 mars 2019

Ended

Dhavalkumar PATEL

Director · since 12 décembre 2017 · until 01 juillet 2024

Ended

Dhavalkumar PATEL

Director · since 12 décembre 2017

Ended

At this address

Other companies at this address

Company	CBE no.
Fondation Emmanuel Janssen● Active	0408.369.901
U C B● Active	0403.053.608
UCB Belgium● Active	0402.040.254
UCB Developed Brands● Active	1017.533.562
UCB Fipar● Active	0403.198.811
UCB PHARMA● Active	0403.096.168
UCB Pillar 2● Active	1011.675.752
UCB Ventures● Active	0667.816.096
UCB Ventures Belgium● Active	0668.388.891
UNITE TVA UCB● Active	0820.436.985

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	23/07/2026	03/07/2025	16/07/2024	21/07/2023	18/07/2022	30/04/2021
General meeting	29/06/2026	30/06/2025	24/06/2024	26/06/2023	27/06/2022	27/04/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

13 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	29/06/2026	23/07/2026	French	PDF
Full model	31/12/2024	30/06/2025	03/07/2025	French	PDF
Full model	31/12/2023	24/06/2024	16/07/2024	French	PDF
Full model	31/12/2022	26/06/2023	21/07/2023	French	PDF
Full model	31/12/2021	27/06/2022	18/07/2022	French	PDF
Full model	31/12/2020	27/04/2021	30/04/2021	French	PDF
Full model	31/12/2019	29/06/2020	22/07/2020	French	PDF
Full model	31/12/2018	24/06/2019	12/07/2019	French	PDF
Full modelCorrection	31/12/2017	25/06/2018	31/07/2018	French	PDF
Full model	31/12/2017	25/06/2018	29/06/2018	French	PDF
Full model	31/12/2016	26/06/2017	28/06/2017	French	PDF
Full model	31/12/2015	04/05/2016	13/06/2016	French	PDF
Full model	31/12/2014	29/06/2015	02/07/2015	French	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

more than 1.000 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 4 active · 15 ended

Active mandates

Alistair HENRY

Director · since 01 juillet 2024

Active

Denelle J. WAYNICK JOHNSON

Director · since 01 avril 2023

Active

Sandrine DUFOUR

Director · since 28 septembre 2020

Active

Jean-Luc FLEURIAL

Director · since 12 décembre 2017

Active

Ended mandates

William SILBEY

Director · since 22 mars 2019 · until 31 mars 2023

Ended

William SILBEY

Director · since 22 mars 2019

Ended

Dhavalkumar PATEL

Director · since 12 décembre 2017 · until 01 juillet 2024

Ended

Dhavalkumar PATEL

Director · since 12 décembre 2017

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Other02/01/2026
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF
Mandates02/10/2025
DEMISSIONS, NOMINATIONS
PDF
Other11/06/2025
DIVERS
PDF
Other12/05/2025
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - DIVERS
PDF
Other18/03/2025
DIVERS
PDF
Other02/01/2025
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF
Mandates18/07/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates04/08/2023
DEMISSIONS, NOMINATIONS
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 2025113,8 M €↑
2024
Annual accounts 20248,5 M €↑
24/06/2024
nominationAlistair Henry — administrateur
24/06/2024
nominationMazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL — commissaire aux comptes
2023
Annual accounts 2023-676,9 M €↓
01/04/2023
nominationDenelle J. Waynick Johnson — administrateur
2022
Annual accounts 2022-519,5 M €↓
15/07/2022
apport
2021
Annual accounts 2021-510,4 M €↓
2020
Annual accounts 2020-225,3 M €↑
2019
Annual accounts 2019-569,4 M €↑
2018
Annual accounts 2018-827,9 M €↓
2015
Annual accounts 2015-290,8 M €↓
2014
Annual accounts 20149,6 M €
24/12/2013
IncorporationPrivate limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

UCB BIOPHARMA

Overview

What does UCB BIOPHARMA do?

Trend over 10 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline